Compare Illumina, Inc. (ILMN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Chase & Co — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while JPMorgan Chase & Co trades at $362.23 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 33× Illumina, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | JPM | |
|---|---|---|
Market Cap | $28.96B | $956.39B |
Sector | Health | Financials |
52-Week High | $205.10 | $362.04 |
52-Week Low | $91.00 | $282.84 |
Enterprise Value | $30.32B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings show a Q2 2026 beat ($7.59 actual vs. $5.59 expected), though Q4 2025 missed estimates. Revenue grew to $181.85B in 2025, with a net income margin of 33.38% and ROE of 18.43%, but cash flow trends remain volatile with negative net cash flow in 2025.
The outlook is positive with strong profitability and analyst support, but risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI advancements. The stock offers upside to the price target, yet investors should monitor cash flow stability and macroeconomic headwinds highlighted by CEO Jamie Dimon's recent warnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
